20 articles
NGP 555 targets toxic brain protein production in healthy volunteers, offering potential early intervention for Alzheimer's prevention.
Italian researchers investigated whether intensive exercise could slow Parkinson's progression by reducing inflammation and boosting protective factors.
The EPICURO trial tests MERIVA® turmeric over 6 months to see if it protects cognition in adults with metabolic syndrome.
Small trial tested whether fish oil and alpha lipoic acid could slow Alzheimer's by reducing oxidative stress markers in blood.
A Phase 1/2 trial tests whether dexmedetomidine can enhance the brain's glymphatic system to clear amyloid and tau during sleep.
A Phase 2 open-label trial explores whether an approved immune drug can raise frataxin protein levels and slow neurological decline in Friedreich Ataxia.
Completed study of 102 older adults tested whether combined interventions can preserve brain volume and improve mobility through muscle-brain axis.
Clinical trial explores how targeted light treatment could restore circadian rhythms and improve brain function in mild cognitive impairment.
A completed Phase 4 trial from India evaluates whether ALA supplementation boosts flunarizine's migraine-prevention power in adolescents.
Nine-year study investigated whether solanezumab could slow memory decline in older adults with brain amyloid plaques.
King's College study tests whether simple chewing and fasting patterns can enhance cognitive function and neurogenesis in older adults.
Probucol, a discontinued cholesterol medication, may boost brain-protective proteins in older adults at risk for dementia.
A double-blind trial tests whether 810nm photobiomodulation can reverse cognitive impairment in long COVID patients at home.
A completed RCT tests whether treating insomnia with CBT-I can improve cognition and slow amyloid buildup in adults aged 60–85.
Italian researchers test plant-based compounds for brain health and quality of life in aging adults with promising early results.
A structured neuroplasticity-based program improved functional performance and emotional well-being in community-dwelling older adults with dementia.
18-month trial tested omega-3 supplementation in 774 older adults with low DHA/EPA levels and memory concerns to prevent cognitive decline.
A first-in-human multiple-ascending-dose trial tests Contraloid, an oral peptide designed to disassemble toxic amyloid-beta oligomers linked to Alzheimer's disease.
A completed trial tests whether daily Nordic berry beverages can sharpen cognition in healthy adults over 12 weeks.
Large 503-patient study tested whether Actovegin could improve thinking and memory problems that persist after stroke recovery.
